See more : Kewaunee Scientific Corporation (KEQU) Income Statement Analysis – Financial Results
Complete financial analysis of Itamar Medical Ltd. (ITMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Itamar Medical Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- UniPharma Co., Ltd. (6621.TWO) Income Statement Analysis – Financial Results
- Million Stars Holdings Limited (8093.HK) Income Statement Analysis – Financial Results
- Relmada Therapeutics, Inc. (RLMD) Income Statement Analysis – Financial Results
- PT. Mitra Adiperkasa Tbk (MAPI.JK) Income Statement Analysis – Financial Results
- QES Group Berhad (0196.KL) Income Statement Analysis – Financial Results
Itamar Medical Ltd. (ITMR)
Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 41.03M | 31.26M | 24.19M | 20.70M | 18.44M | 16.81M | 16.39M | 13.34M | 13.43M |
Cost of Revenue | 12.32M | 6.98M | 5.73M | 5.00M | 4.98M | 4.40M | 4.80M | 4.26M | 3.80M |
Gross Profit | 28.71M | 24.27M | 18.46M | 15.70M | 13.46M | 12.41M | 11.59M | 9.08M | 9.62M |
Gross Profit Ratio | 69.97% | 77.66% | 76.33% | 75.84% | 73.00% | 73.81% | 70.72% | 68.07% | 71.68% |
Research & Development | 6.00M | 4.52M | 3.64M | 4.13M | 3.23M | 2.83M | 2.02M | 1.89M | 1.69M |
General & Administrative | 8.50M | 6.35M | 5.25M | 5.28M | 5.36M | 4.30M | 4.63M | 4.88M | 2.55M |
Selling & Marketing | 24.55M | 18.29M | 12.70M | 12.14M | 14.04M | 10.68M | 8.44M | 7.40M | 5.69M |
SG&A | 33.05M | 24.65M | 17.95M | 17.42M | 19.40M | 14.98M | 13.07M | 12.28M | 8.23M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 849.00K | 52.00K | 113.00K | 117.00K | 217.00K |
Operating Expenses | 39.06M | 29.17M | 21.58M | 21.55M | 23.47M | 17.87M | 15.20M | 14.29M | 10.14M |
Cost & Expenses | 51.38M | 36.15M | 27.31M | 26.55M | 28.45M | 22.27M | 20.00M | 18.54M | 13.94M |
Interest Income | 713.00K | 454.00K | 93.00K | 1.39M | 547.00K | 176.00K | -571.00K | 714.00K | 121.00K |
Interest Expense | 562.00K | 284.00K | 794.00K | 4.43M | 4.61M | 4.19M | 2.51M | 4.83M | 2.12M |
Depreciation & Amortization | 1.82M | 1.29M | 481.00K | 509.00K | 434.00K | 367.00K | 324.00K | 400.00K | 330.00K |
EBITDA | -8.43M | -3.66M | -330.00K | -280.00K | -9.23M | 2.44M | -313.00K | -7.73M | 2.76M |
EBITDA Ratio | -20.55% | -11.71% | -1.36% | -1.35% | -50.04% | 14.53% | -1.91% | -57.95% | 20.57% |
Operating Income | -10.34M | -4.89M | -3.12M | -5.85M | -10.01M | -5.46M | -3.61M | -5.21M | -515.00K |
Operating Income Ratio | -25.21% | -15.66% | -12.90% | -28.25% | -54.30% | -32.48% | -22.02% | -39.04% | -3.84% |
Total Other Income/Expenses | -468.00K | -337.00K | 1.52M | 632.00K | -4.26M | 3.35M | 458.00K | -7.76M | 831.00K |
Income Before Tax | -10.81M | -5.23M | -1.61M | -5.22M | -14.27M | -2.11M | -3.15M | -12.96M | 316.00K |
Income Before Tax Ratio | -26.35% | -16.73% | -6.64% | -25.20% | -77.40% | -12.57% | -19.23% | -97.20% | 2.35% |
Income Tax Expense | 127.00K | 37.00K | 124.00K | 85.00K | 131.00K | 135.00K | 124.00K | -44.00K | -201.00K |
Net Income | -10.94M | -5.27M | -1.73M | -5.30M | -14.40M | -2.25M | -3.28M | -12.92M | 517.00K |
Net Income Ratio | -26.66% | -16.85% | -7.15% | -25.61% | -78.11% | -13.37% | -19.99% | -96.87% | 3.85% |
EPS | -0.79 | -0.46 | -0.17 | -0.60 | -1.65 | -0.35 | -0.56 | -2.82 | 0.03 |
EPS Diluted | -0.79 | -0.46 | -0.17 | -0.52 | -1.65 | -0.29 | -0.46 | -2.82 | 0.03 |
Weighted Avg Shares Out | 13.85M | 11.54M | 10.13M | 8.80M | 8.75M | 6.39M | 5.83M | 4.58M | 16.42M |
Weighted Avg Shares Out (Dil) | 13.85M | 11.54M | 10.13M | 10.13M | 8.75M | 7.73M | 7.15M | 4.58M | 16.42M |
Itamar Medical Ltd. Sponsored ADR (ITMR) Reports Q3 Loss, Lags Revenue Estimates
Itamar Medical Ltd. Sponsored ADR (ITMR) delivered earnings and revenue surprises of -63.33% and 0.98%, respectively, for the quarter ended September 2021.
Analysts Estimate Itamar Medical Ltd. Sponsored ADR (ITMR) to Report a Decline in Earnings: What to Look Out for
Itamar Medical Ltd. Sponsored ADR (ITMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Itamar Medical Ltd. with ZOLL Medical Corporation
New York, New York--(Newsfile Corp. - September 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Itamar Medical Ltd. (NASDAQ: ITMR) ("Itamar" of the "Company") stock prior to September...
ITMR Stock: The $538M Reason Why Itamar Medical Is Soaring 45% on Monday
ZOLL Medical isn't sleeping on the chance to acquire sleep apnea pioneer Itamar. Shares of ITMR stock are reacting well to the news.
Why Itamar Medical Stock Is Skyrocketing Today
Zoll Medical plans to acquire the small producer of medical devices.
ITMR Stock: Why It Significantly Increased Today
The stock price of Itamar Medical (NASDAQ: ITMR) increased by over 40% pre-market. This is why it happened.
Itamar Medical Goes Private In $538M Deal: All You Need To Know
ZOLL Medical Corporation, an Asahi Kasei company, has agreed to acquire Itamar Medical Ltd (NASDAQ: ITMR) for a total value of approximately $538 million. Itamar Medical focuses on the development and commercialization of non-invasive medical devices and solutions to diagnose respiratory sleep disorders.
ZOLL Medical Corporation Signs Definitive Agreement to Acquire Itamar Medical
CHELMSFORD, Mass. & CAESAREA, Israel--(BUSINESS WIRE)--ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Itamar™ Medical Ltd. (Nasdaq and TASE: ITMR), a medical device and digital health company focused on the integration of...
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors
CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the...
Itamar Medical Ltd.'s (ITMR) CEO Gilad Glick on Q2 2021 Results - Earnings Call Transcript
Itamar Medical Ltd.'s (ITMR) CEO Gilad Glick on Q2 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports